Cardiorentis AG v Iqvia Ltd & Anor [2022] EWHC 250 (Comm) (10 February 2022)

Cardiorentis AG v Iqvia Ltd & Anor [2022] EWHC 250 (Comm) (10 February 2022)

The court found that while there were some protocol deviations and eligibility errors in the TRUE-AHF trial, Cardiorentis failed to prove that these were caused by breaches of contract by IQVIA or that they rendered the study unreliable or of no value. The claim for wasted costs therefore failed. IQVIA was entitled to recover unpaid fees under the contract, subject to any set-off for minor breaches not causative of loss.

Citation
[2022] EWHC 250 (Comm)
Parties
Claimant: Cardiorentis AG; First Defendant: IQVIA Limited; Second Defendant: IQVIA RDS, Inc.
Jurisdiction
England and Wales
Judgment Date
10 February 2022
Procedural Posture
Commercial Court (qbd) Contract Dispute / Final Judgment After Trial
Outcome
Claim dismissed; counterclaim allowed
Legal Topics
Breach of Contract, Damages for Wasted Costs, Clinical Trial Protocols, Good Clinical Practice (gcp), Limitation of Liability, Counterclaim for Unpaid Fees
Contract Law Pharmaceutical Law Clinical Trials Regulation Breach of Contract Damages for Wasted Costs Clinical Trial Protocols Good Clinical Practice (gcp) Limitation of Liability +1 more

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 3 Authorities cited 4 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Cardiorentis AG

Claimant

IQVIA Limited

First Defendant

IQVIA RDS, Inc.

Second Defendant

Procedural Posture

Commercial Court (qbd) Contract Dispute / Final Judgment After Trial

Legal Issues

  1. 1 Whether IQVIA breached contractual obligations in the conduct of the TRUE-AHF clinical trial
  2. 2 Whether such breaches caused Cardiorentis to incur wasted costs
  3. 3 Whether Cardiorentis is liable for unpaid fees to IQVIA under the contract

Ratio Decidendi

The court found that while there were some protocol deviations and eligibility errors in the TRUE-AHF trial, Cardiorentis failed to prove that these were caused by breaches of contract by IQVIA or that they rendered the study unreliable or of no value. The claim for wasted costs therefore failed. IQVIA was entitled to recover unpaid fees under the contract, subject to any set-off for minor breaches not causative of loss.

Court Disposition

Claim dismissed; counterclaim allowed

Orders

  • Cardiorentis's claim for damages is dismissed.
  • IQVIA's counterclaim for unpaid fees is allowed, subject to calculation of the precise sum due.